Physician profile
Amy Lane
NPI 1659475911
$2,011.94
in general payments reported to CMS, 2019-2025
12 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $435 · 2022: $533 · 2023: $730 · 2024: $115 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $671.47 | 2021-2024 | |
| Corium, LLC | $314.44 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $266.29 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $223.61 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.27 | 2022-2024 | Caplyta |
| Alkermes, INC. | $117.80 | 2021 | |
| Novo Nordisk INC | $84.31 | 2025 | Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $73.68 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $46.02 | 2023 | Auvelity |
| Glaxosmithkline, LLC. | $28.78 | 2023 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Lundbeck LLC | $27.82 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $21.45 | 2023 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.